Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.
Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, Samson J, Lesclous P, Laredo JD, Namer M. Tubiana-Hulin M, et al. Among authors: namer m. Crit Rev Oncol Hematol. 2009 Jul;71(1):12-21. doi: 10.1016/j.critrevonc.2008.10.009. Epub 2008 Dec 12. Crit Rev Oncol Hematol. 2009. PMID: 19070505 Review.
Radiotherapy for invasive breast cancer: guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence.
Belkacémi Y, Fourquet A, Cutuli B, Bourgier C, Hery M, Ganem G, Marsiglia H, Namer M, Gligorov J, Azria D; French Expert Review Board of Nice/Saint-Paul de Vence. Belkacémi Y, et al. Among authors: namer m. Crit Rev Oncol Hematol. 2011 Aug;79(2):91-102. doi: 10.1016/j.critrevonc.2010.06.002. Epub 2010 Jul 7. Crit Rev Oncol Hematol. 2011. PMID: 20615725
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M. Coudert BP, et al. Among authors: namer m. J Clin Oncol. 2007 Jul 1;25(19):2678-84. doi: 10.1200/JCO.2006.09.9994. Epub 2007 May 21. J Clin Oncol. 2007. PMID: 17515572 Clinical Trial.
[Node negative breast cancer. Beyond international consensus: a pragmatic approach].
Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M. Penault-Llorca F, et al. Among authors: namer m. Bull Cancer. 2011 Jul;98(7):807-25. doi: 10.1684/bdc.2011.1395. Bull Cancer. 2011. PMID: 21727059 French.
Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, Diéras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P. Spielmann M, et al. Among authors: namer m. Oncology. 2001;60(4):303-7. doi: 10.1159/000058524. Oncology. 2001. PMID: 11408796 Clinical Trial.
239 results